Epidermolysis Bullosa Market Insights, Share, Size, Companies, and Forecast 2032

DelveInsight's Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Epidermolysis Bullosa Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Epidermolysis Bullosa Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.

Download a sample copy of the report @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Epidermolysis Bullosa: An Overview
Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma. To date, there is no treatment or cure for EB. EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes, which form the intraepidermal adhesion and dermo-epidermal anchoring complex within the basement membrane zone (BMZ) of the skin and mucosae.

Key highlights of the Epidermolysis Bullosa Market Report
• Assessments as per DelveInsight's analysts show that the total prevalent population of Epidermolysis Bullosa in seven major markets was 41,509 in 2017.
• The total diagnosed prevalent cases of Epidermolysis Bullosa in 7MM was 39,433 in 2017.
• In 2017, there were 26,104 prevalent cases of Epidermolysis Bullosa in the United States.
• In 2017, there was a total of 24,799 diagnosed prevalent cases of Epidermolysis Bullosa in the United States.

Epidermolysis Bullosa Epidemiology Segmentation in the 7MM
• Total Prevalent Population
• Total Diagnosed Prevalent Population
• Type-specific Diagnosed Prevalence

Discover more information of the report @ https://www.delveinsight.com/report-store/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Epidermolysis Bullosa Market Size
The market size of Epidermolysis Bullosa (EB) in seven major markets (7MM) is estimated to be approximately USD 2,296.31 million in 2017. The United States accounts for the highest market size of Epidermolysis Bullosa, in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the EU5 countries, the UK had the highest market size with USD 195.25 million in 2017, while Spain had the lowest market size of Epidermolysis Bullosa with USD 35.99 million in 2017.

Epidermolysis Bullosa Treatment Market

Currently, there is no cure for RDEB, although considerable progress has been made in testing novel treatments including gene therapy (lentiviral and gamma retroviral vectors for COL7A1 supplementation in keratinocytes and fibroblasts), as well as cell therapy (use of allogeneic fibroblasts, mesenchymal stromal cells (MSCs), and bone marrow transplantation (BMT)). A study was conducted by Ellie et al., titled "Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa", to review current treatment modalities available as well as novel and emerging therapies in the treatment of RDEB. Pain is a common and constant feature seen in patients with RDEB and arises from four major sources: skin, pain associated with procedures, bone and gastrointestinal.

For skin care, semi-occlusive dressings that are non-adhesive such as silicone and foam dressings are preferable for treating erosions and reducing skin pain as they absorb exudate and offer some physical protection, thereby providing a moist, clean barrier against bacteria. Opioids in the form of morphine, oxycodone, codeine, and fentanyl are given by a variety of routes including oral, subcutaneous and sublingual are an effective method of relieving most types of pain in RDEB. For esophageal pain, H2 blockers and proton pump inhibitors for gastro-esophageal reflux can be used and systemic steroids can be utilized during episodes of acute esophageal blistering. Tricyclic antidepressants such as amitriptyline and doxepin are taken orally have anecdotally been shown to be beneficial to manage pain in junctional EB.

Epidermolysis Bullosa Market Insights

Epidermolysis bullosa (EB) is a rare genetic disease that causes painful skin blistering. EB can range from mild to severe. There is currently no cure for EB and treatments focus on preventing blisters or managing the wounds caused by the condition. There are different types of EB that are associated with blisters forming in different locations on the body and that vary in severity. Different treatments are used depending on the type of epidermolysis bullosa.

Learn more about the report @ https://www.delveinsight.com/report-store/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Epidermolysis Bullosa Companies
• Amryt Pharma
• Abeona Therapeutics
• Castle Creek Pharmaceuticals
• RegeneRx
• Krystal Biotech
• Fibrocell Technologies
• RHEACELL GmbH
• Holostem Terapie Avanzate
• Stemrim, and several others

Table of Content
1. Key Insights
2. Executive Summary
3. Epidermolysis Bullosa (EB) Market Overview at a Glance
4. Epidermolysis Bullosa (EB): Disease Background and Overview
5. Case Reports
6. Epidemiology and Patient Population
7. Country Wise-Epidemiology of Epidermolysis Bullosa
8. Treatment and Management of Epidermolysis Bullosa (EB)
9. Unmet Needs
10. Emerging Drugs
11. Epidermolysis Bullosa: 7 Major Market Analysis
12. Market Outlook: The United States
13. Market Outlook: Europe
14. Market Outlook: Japan
15. Market Drivers
16. Market Barriers
17. SWOT analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Discuss with our Business Consultant @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.